PYRAMID-ANALYTICS
16.6.2022 09:02:14 CEST | Business Wire | Press release
BIG DATA ANALYTICS CONFERENCE – Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, announced today that Tom Warren has been appointed Regional Managing Director, UK and Ireland (UKI). Warren brings with him twelve years of experience leading high achieving teams, alongside his previous experience as a professional rugby player, to build upon Pyramid’s growth in the UKI. The company’s customers in the UKI include Ann Summers, Liberty London, and Premier Foods.
The appointment follows Pyramid Analytics’ recent oversubscribed US $120MM Series E funding round, which was announced at a special event on May 9 from Tower Bridge in London. Pyramid is doubling down on its investment in the UKI, a leading market for decision intelligence adoption. In 2022, the UK tech ecosystem hit a landmark valuation of $1 trillion . At the centre of this tech success story is London. Pyramid plans to double its headcount in London over the coming months, to then use London as a base to support its European expansion. The appointment of Warren highlights Pyramid’s commitment to, and ambitions for, the UK and Ireland.
Key Points:
- Pyramid Analytics, a decision intelligence platform provider, hires experienced technology sector leader Tom Warren to accelerate UKI growth. Warren has twelve years leading successful teams and customer relationship management.
- Pyramid expanding investment in UKI talent, sales and marketing, and partner expansion.
- Warren’s appointment is the first in a series of planned business development initiatives to support customer success and strategic accounts in this region.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
Warren’s remit is to build out the UK and Ireland business, which will involve enterprise sales, business development, and channel and solutions engineering functions. Having started his career as a professional rugby player, Tom Warren is excited about the challenge ahead.
Meet our new Managing Director
Warren had a successful career as a professional rugby player for Worcester Warriors , London Irish , Grand Parma in Italy and finally at Esher RFC . This included a Division 1 title for Worcester in 2004 and playing in an English Premiership semi-final and European Challenge Cup final for London Irish in 2006. After his retirement, Warren initially turned his hand to coaching as the Scrum Coach and Director of the Academy at Esher.
Since then, he has had a successful career in sales. His most recent role was as Area VP Northern Europe at the cloud-based logistics platform Bringg where he was responsible for building out the EMEA sales team. In a previous role as Senior Director for EMEA Enterprise renewals at Blue Prism, he successfully increased customer renewals from 82% to 88%, which accounted for a 113% increase in the 2019 financial year. He was also Regional Sales Director at ServiceNow, where he set up the first UK Commercial sales team and consistently exceeded targets for delivering new business to help grow the UK business.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics: “Tom has brought a vast wealth of expertise and insight to the Managing Director role. He has a strong history of leading impressively successful sales and customer relationship teams and has helped multiple companies expand their sales outreach into the EMEA region.
“As a former professional rugby player and with over twelve years of heading sales teams, we knew that Tom would bring strong leadership skills, courage and energy to our growing team here at Pyramid. We believe that Tom is the right individual to lead our already high performing team to continue our growth in the UK and Ireland, following our phenomenal Series E funding round performance.”
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics : “Pyramid is what’s next in analytics and the UK is what’s next for Pyramid. I am really excited to be joining Pyramid Analytics and even more so to be joining a successful and high performing team, which has been behind their expansion in the UK and Ireland.
“Our Series E funding round earlier this month was a real statement of intent from the company, showcasing our ambition to expand our UK and Ireland operations so that Decision Intelligence can continue to transform the way businesses operate in the region. I look forward to contributing to this great company and working towards our European expansion.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners , Jerusalem Venture Partners (JVP), Sequoia Capital , and Viola Growth . Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
